These are the top coronavirus vaccines to watch

We are tracking 200 experimental vaccines aimed at ending the pandemic, a scientific quest moving at record-breaking speed.

Updated Oct. 26 at 11:15 a.m.
170+ vaccinesare being tested in animals and lab experiments
Phase 1
12 vaccinesare being tested in a small number of healthy, young people to assess safety and correct dose
Phase 2
15 vaccinesare broadened to a larger group of people, including people at higher risk of illness
Phase 3
10 vaccinesare being tested in thousands of people to check their effectiveness and safety
0 vaccineshave been determined to provide benefits that outweigh known and potential risks
  • Recent developments
  • Oct. 24 | Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume
  • Oct. 22 | FDA advisory committee debates safety and efficacy standards for a coronavirus vaccine
  • Oct. 22 | Moderna’s coronavirus trial is fully enrolled, 37 percent of participants are minorities
  • Oct. 16 | Pfizer says it will not have a coronavirus vaccine until late November, allaying fears of a rush for approval before Election Day

The worldwide effort to create a vaccine for the novel coronavirus kicked off in January, soon after scientists in China posted online the genome of a virus causing a mysterious pneumonia. Vaccine development usually takes years and unfolds step by step. Experimental vaccine candidates are created in the laboratory and tested in animals before moving into progressively larger human clinical trials.

These steps are now overlapping in the race to find a vaccine for a global disease that has killed hundreds of thousands of people. Human testing began in some cases before animal studies were finished. As companies launch small Phase 1 trials intended to establish the correct dose, they already are planning the Phase 3 trials that evaluate whether the vaccines are effective and safe.

[A vaccine, or a spike in deaths: How America can build herd immunity to the coronavirus]

No steps are being skipped, top government officials have repeatedly promised, and vaccines will not be considered for approval in the United States until after a large, Phase 3 trial. The Food and Drug Administration, which has the ultimate say on whether a vaccine has been proved safe and effective, says a vaccine for covid-19, the disease caused by the coronavirus, will need to prevent disease or decrease symptoms in at least 50 percent of those who receive it. The effectiveness of the flu vaccine ranges from 40 to 60 percent, according to the Centers for Disease Control and Prevention.

Other countries may use different standards or authorize vaccines without waiting for proof they are safe and effective. Russia announced it would begin using its vaccine in people at high risk for the virus in August, before starting its Phase 3 trial. China has authorized a vaccine for use in members of the military.

Unprecedented speed

Researchers in the United States set an audacious goal in January to develop a coronavirus vaccine within 12 to 18 months. This would be a world record. The mumps vaccine is considered to be the fastest to move, in four years, from scientific concept to approval in 1967. The quest for an HIV vaccine continues, 36 years and counting.

Coronavirus vaccines are moving much faster, partly because governments are taking on the financial risk of developing a vaccine that may not work. Through Operation Warp Speed, the U.S. government has invested about $9.5 billion to speed up development and jump-start manufacturing before research is finished.

New technologies

Advancements in science and technology have given researchers new tools to try against the coronavirus. Scientists can deliver genetic material into the body’s cells, turning them into vaccine factories and skipping time-consuming steps such as manufacturing viral proteins or growing the whole virus in chicken eggs.

Technology used:

Nucleic acid
Phase 1
Phase 2
Phase 3

The core of the coronavirus SARS-CoV-2 is a single strip of ribonucleic acid (RNA) surrounded by a protein shell. The virus is named for the iconic spikes that project from its center like a crown, or “corona” in Latin. These spike proteins aren’t just decoration. They are critical for the virus to get inside cells and make copies of itself.

Vaccines work by teaching the body’s immune system to recognize and block viruses. Each category of vaccine technology works under this basic principle. Vaccines aim to activate the immune system’s T-helper cells, which are responsible for detecting the presence of a virus. They instruct B-cells to create antibodies that block the virus from being able to replicate and T-killer cells to destroy infected cells. Some vaccines may activate only part of this immune response.

Here is a look at how different vaccine technologies being developed around the world would ideally elicit an immune response to prevent SARS-CoV-2 in humans. Each vaccine may vary somewhat in how it works, but each would generally follow these steps.

Vaccines using nucleic acid (DNA and RNA)

DNA vaccines contain genetic material that carries the blueprint for the spike protein. To get the DNA into cells, researchers use an electrical pulse to disrupt the cell membrane. Once inside, the DNA is used as a template to create spike protein.

RNA vaccines contain a strip of genetic material within a fat bubble. Once inside the cell, the RNA generates a protein found on the surface of the virus. The immune system, presented with the protein, learns to recognize the virus.

These vaccines have the advantage of speed — they can be quickly designed and manufactured. But they have never been approved for use outside of medical research and will likely require two doses.

Nucleic acid vaccines, developed by...

*Vaccine currently in distribution that has not been fully tested.

Viral-vectored vaccines

Some vaccines use a virus that has been engineered to be harmless to ferry a gene from the coronavirus into cells. The gene codes for a distinctive part of the coronavirus, and the immune system learns to recognize it.

Viral-vectored vaccines can be designed quickly. One concern is that people can develop immunity to the viral vector, making this approach potentially less useful if booster shots need to be given.

Viral-vectored vaccines, developed by...

*Vaccine currently in distribution that has not been fully tested.

Subunit vaccines

Some traditional vaccines work by delivering viral proteins to cells. The technologies to manufacture those protein fragments vary, but companies are using insect cells and yeast. The hepatitis B vaccine relies on a viral protein created by genetically engineered yeast.

Subunit vaccines, developed by...

*Vaccine currently in distribution that has not been fully tested.

Weakened or inactivated virus vaccines

In a more old-fashioned approach, the virus is weakened so that it does not cause disease, but still triggers the immune system’s defenses. The vaccine for measles, mumps and rubella uses this approach.

Inactivated virus vaccines contain dead virus, incapable of infecting people but still able to instruct the immune system how to mount a defensive reaction against an infection. The polio vaccine invented by Jonas Salk used this approach, and flu vaccines use this technology.

These vaccines typically take longer to manufacture.

Weakened and inactivated virus vaccines, developed by...

*Vaccine currently in distribution that has not been fully tested.

Other vaccines

Information on the technology platform being used was not available for all the experimental vaccines. Some vaccines being tested do not specifically target the coronavirus, but aim to increase the body’s first line of immune defenses.


An earlier version of the graphic illustrating how subunit vaccines work was mislabeled (Aug. 14, 2020).

About this story

Data for vaccine developments comes from FasterCures, a center for the Milken Institute, and Post reporting. FasterCures tracks publicly available information on covid-19 vaccine development from a variety of sources, such as preprints from medRxiv and bioRxiv; clinical trial registries from the United States, European Union and the World Health Organization's International Clinical Trials Registry Platform, which includes clinical trial information from China; WHO documents on covid-19; and news reports.

Other sources: Dr. Angela Rasmussen, Columbia University, Center for Infection and Immunity; National Institutes of Health; Centers for Disease Control and Prevention; Nature Research.

Have we missed something? Please email us with updates and questions.

Headshot of Aaron Steckelberg
Aaron Steckelberg is a senior graphics editor who creates maps, charts and diagrams that provide greater depth and context to stories over a wide range of topics. He has worked at the Post since 2016.
Headshot of Carolyn Y. Johnson
Carolyn Johnson is a science reporter. She previously covered the business of health and the affordability of health care to consumers. FollowFollow
Headshot of Gabriel Florit
Gabriel Florit is a graphics reporter working with augmented reality. Before joining The Washington Post in March 2017, he spent four years as a graphics reporter at the Boston Globe.FollowFollow
Headshot of Chris Alcantara
Chris Alcantara is a graphics reporter at The Washington Post, where he uses code and data to tell visual stories on a variety of subjects, including politics and technology. He joined The Post in 2016.FollowFollow